ReviewBMC pulmonary medicine2026
Diagnosis and management of pleural mesothelioma: three unique cases and review of the literature.
Review in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesothelioma is a rare pleural tumor. Compared to diffuse pleural mesothelioma, localized pleural mesothelioma carries a better prognosis and may be managed with surgical resection. Among histologic subtypes, the sarcomatoid variant is the least common but is associated with the poorest outcome. Diagnosis remains challenging, with immunohistochemistry playing a central role in confirming the disease. While surgical resection is the cornerstone of management, chemotherapy, immunotherapy and radiotherapy are considered in unresectable cases. Overall, mesothelioma continues to carry a poor prognosis. CASE PRESENTATION: We describe three cases of pleural mesothelioma that posed diagnostic and therapeutic challenges. The first case involved a rapidly progressive sarcomatoid mesothelioma, initially raising concern for Ewing’s sarcoma, which was excluded based on negative immunohistochemical markers. The second case was an epithelioid mesothelioma successfully treated with extrapleural pneumonectomy followed by adjuvant chemotherapy and immunotherapy, resulting in prolonged survival. The third case, the only one with documented asbestos exposure, represents the first reported instance of synchronous epithelioid mesothelioma and invasive ductal carcinoma of the breast.
conclusionMesothelioma is a rare and complex pleural malignancy that may present in atypical ways, complicating both diagnosis and management. These cases underscore the importance of immunohistochemical profiling, highlight the value of multidisciplinary diagnostic approaches, and reaffirm the pivotal role of surgery within the therapeutic algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.